Newsroom

Jan 06, 2023

Orca Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

View

Dec 12, 2022

Orca Bio Presents Encouraging Interim Clinical Data on Orca-Q in Haploidentical Allogeneic Hematopoietic Stem Cell Transplants at 64th ASH Annual Meeting

View

Dec 10, 2022

Orca Bio Presents Data Demonstrating its Lead Investigational High-Precision Cell Therapy Orca-T Significantly Improved Relapse-Free Survival at 64th Annual Meeting

View

Nov 03, 2022

Orca Bio to Present Four Abstracts at the 64th American Society of Hematology Annual Meeting, Including Updated Relapse-Free Survival Data with Orca-T and the First Clinical Data for Orca-Q

View

Sep 08, 2022

Orca Bio Expands Manufacturing Capabilities to Develop and Commercialize its Precision Cell Therapies

View

Aug 02, 2022

Orca Bio Announces the Precision-T Phase 3 Study is Open and Enrolling Patients at Transplant Centers Across the U.S.

View

May 12, 2022

Orca Bio to Present New Clinical Data on Orca-T at the European Hematology Association 2022 Congress

View

Apr 25, 2022

Orca Bio Presents Positive Data Reinforcing Clinical Profile and Manufacturing Reliability of Orca-T at 2022 Transplantation & Cellular Therapy ASTCT and CIBMTR Tandem Meetings

View